Zoryve Generic Name & Formulations
Legal Class
Rx
General Description
Roflumilast 0.3%; crm.
Pharmacological Class
Phosphodiesterase 4 (PDE4) inhibitor.
How Supplied
Crm—60g
Manufacturer
Generic Availability
NO
Mechanism of Action
Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3′,5′-adenosine monophosphate (cyclic AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP. The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.
Zoryve Indications
Indications
Plaque psoriasis, including intertriginous areas.
Zoryve Dosage and Administration
Adults and Children
<6yrs: not established. ≥6yrs: Apply to the affected area(s) once daily; rub in completely.
Zoryve Contraindications
Contraindications
Moderate to severe liver impairment (Child-Pugh B or C).
Zoryve Boxed Warnings
Not Applicable
Zoryve Warnings/Precautions
Warnings/Precautions
Not for oral, ophthalmic, or intravaginal use. Labor & delivery: avoid. Pregnancy. Nursing mothers: avoid direct infant exposure.
Zoryve Pharmacokinetics
Absorption
Mean ± SD systemic exposure (AUC0-24): 72.7 ± 53.1 (adults); 25.1 ± 24.0 (adolescents 13–16yrs); 75.6 ± 87.3 (pediatrics 6–<12yrs).
Distribution
Plasma protein bound: ~99%.
Elimination
Half-life: 4.0 days.
Zoryve Interactions
Interactions
May be potentiated by systemic CYP3A4 inhibitors, dual CYP3A4/CYP1A2 inhibitors (eg, erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine), oral contraceptives containing gestodene + ethinyl estradiol; consider risks vs benefits prior to concomitant use.
Zoryve Adverse Reactions
Adverse Reactions
Diarrhea, headache, insomnia, application site pain, upper respiratory tract infections, urinary tract infections.
Zoryve Clinical Trials
See Literature
Zoryve Note
Not Applicable
Zoryve Patient Counseling
See Literature
Images
